71 percent of patients had pathological complete response; 7 percent experienced grade 3 treatment-related adverse events

All lesions in children and adults resolved after an average of 2.1 treatments

Agent Orange exposure linked to higher odds of AM compared with patients with cutaneous melanoma and controls with no melanoma

Ensemble integrating three architectures achieved area under the curve of 0.9208, outperforming individual models

Patients often experience climate-related triggers, but few reported that their dermatologist addressed these concerns

28.06 percent of the association between DII/DOBS and skin cancer was mediated by PhenoAge

Due to overlap with other pediatric conditions and low clinical suspicion, diagnostic delays are common

Psoriatic arthritis is often missed until irreversible joint damage has occurred, but dermatology clinicians can change that. This article highlights how routine use of...

Median lead time 2.7 months between first positive ctDNA and clinical recurrence

Transmasculine individuals have the highest acne risk in the first year after initiation of testosterone

Significant associations seen for autoimmune, endocrine, neurological, and mental health comorbidities

Significantly reduced risk for disease progression or death seen with toripalimab versus dacarbazine, including in acral melanoma

Higher percentage reductions in Eczema Area and Severity Index seen with 80 mg ICP-332, 120 mg ICP-332 versus placebo

69.5 percent of patients demonstrated improvement or remission of psoriasis after metabolic bariatric surgery for obesity

In 2024, 31.7 percent of adults and 29.5 percent of children had diagnosed seasonal allergy, eczema, or food allergy

Findings show significant risk for asthma, allergic rhinitis, or atopic dermatitis

Severity of Alopecia Tool score ≤20 at week 24 achieved by 34.9, 40.6, and 9.0 percent of patients receiving 4 mg, 8 mg ivarmacitinib,...

Median progression-free survival 7.5 months among 22 patients who underwent surgery for vaginal or vulvar melanoma

Biologics do not affect cancer progression, while predictors of progression include advanced cancer stage, higher comorbidity burden

Women had improved survival without immunotherapy, but similar survival with immunotherapy

Review of randomized controlled trials shows interventions improve psoriasis severity and quality of life

Data from four randomized clinical trials confirm benefits by day 2 in atopic dermatitis, prurigo nodularis

Negligible additional risk for recurrence seen after 5FU or surgical excision; negligible risk for cutaneous squamous cell carcinoma reported from treated BD